Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Friday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $0.80 on Friday. The company has a market cap of $11.17 million, a P/E ratio of -0.28 and a beta of 1.61. The firm’s 50 day moving average is $0.46 and its two-hundred day moving average is $0.43. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.23.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.